



Announcement of AGM and Publication of AR

October 30, 2023

RNS Number : 7470R

Renalytix PLC

30 October 2023

Renalytix plc
("Renalytix" or the "Company")

Announcement of AGM and
Publication of Annual Report 2023

LONDON and SALT LAKE CITY, UT October 30, 2023 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that its Annual General Meeting ("AGM") will be held in-person on 15 December 2023 at 15.30 p.m. (GMT) at 6 Stratton Street Mayfair, London W1J 8LD.

In addition, the Company's Annual Report for the year ended 30 June 2023 has now been published on the Company's website: <https://investors.renalytix.com/financials-and-filings/annual-and-half-year-reports>

The 2023 Annual Report will be posted to shareholders who have not consented to receive electronic communications.

To help with practical arrangements for the AGM, any Shareholder wishing to attend is requested to register first by contacting Walbrook PR via email at renalytix@walbrookpr.com or by telephone at +44 (0)20 7933 8790.

For further information, please contact:

Renalytix plc
James McCullough, CEO

www.renalytix.com
Via Walbrook PR

Stifel (Nominated Adviser, Joint Broker)
Alex Price / Nicholas Moore / Nick Harland / Samira Essebiyea

Tel: 020 7710 7600

Investec Bank plc (Joint Broker)
Gary Clarence / Shalin Bhamra

Tel: 020 7597 4000

Walbrook PR Limited
Paul McManus / Alice Woodings
CapComm Partners
Peter DeNardo

Tel: 020 7933 8780 or renalytix@walbrookpr.com
Mob: 07980 541 893 / 07407 804 654

Tel: 415-389-6400 or investors@renalytix.com

About Renalytix

Renalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory services company that is the global founder and leader in the new field of bioprognosis™ for kidney health. The leadership team, with a combined 200+ years of healthcare and in-vitro diagnostic experience, has designed its KidneyIntelX laboratory developed test to enable risk assessment for rapid progressive decline in kidney function in adult patients with T2D and early CKD (stages 1-3). We believe that by understanding how disease will progress, patients and providers can take action early to improve outcomes and reduce overall health system costs. For more information, visit www.renalytix.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

ACSZBLFXXBLXFBE